IO Frontiers World 2019


Chris Sheldon

Dr Chris Sheldon

Head of Oncology Search & Evaluation, Oncology Business Unit, AstraZeneca

Chris has worked in the UK at AstraZeneca (AZ) for over 15 years and is currently Head of Oncology Search & Evaluation in AZ’s Strategy team in its Oncology Business Unit (OBU). Chris and his team are responsible for scouting of new oncology technologies and leading the technical evaluation of new M&A, in-licensing, out-licensing (divestment) and collaboration opportunities in clinical stage oncology. Most recently, he led the evaluation of AstraZeneca’s recent majority $4 billion stake investment in Acerta Pharma for Calquence (acalabrutinib), as well as multiple novel immuno-oncology combination deals for AstraZeneca’s immune checkpoint inhibitor Imfinzi (durvalumab), including a recently announced Phase III collaboration with Incyte.

Prior to this Chris worked in early stage oncology business development and was involved in all aspects of evaluation, due diligence and negotiation of deals. Before his business development career, Chris worked in discover research at AstraZeneca as a senior research chemist. He also holds a Ph.D. in chemistry from the University of Bristol, UK and a first class honours degree from the University of Sheffield, UK.

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy